NO20064820L - Tetrahydrokarbazoler og derivater - Google Patents

Tetrahydrokarbazoler og derivater

Info

Publication number
NO20064820L
NO20064820L NO20064820A NO20064820A NO20064820L NO 20064820 L NO20064820 L NO 20064820L NO 20064820 A NO20064820 A NO 20064820A NO 20064820 A NO20064820 A NO 20064820A NO 20064820 L NO20064820 L NO 20064820L
Authority
NO
Norway
Prior art keywords
diseases
alzheimer
disease
compounds
pharmaceutically acceptable
Prior art date
Application number
NO20064820A
Other languages
English (en)
Inventor
Henrietta Dehmlow
Raffaello Masciadri
Bernd Kuhn
Matthew Blake Wright
Narendra Panday
Hasane Ratni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20064820L publication Critical patent/NO20064820L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Foreliggende oppfinnelse angår forbindelser med formel (I) hvor R1, R2, R3, R4, R5, X1, X2, X3, X4, n og k er definert i beskrivelsen og kravene samt farmasøytisk akseptable salter og/eller farmasøytisk akseptable estere derav. Forbindelsene er anvendelige ved behandling og forebygging av sykdommer som er modulert ved LXRa- og/eller LXR(3-agonister, omfattende økte lipid- og kolesterolnivåer, spesielt lav HDL-kolesterol, høy LDL-kolesterol, aterosklerotiske sykdommer, diabetes, spesielt ikke-insulinavhengig diabetes mellitus, metabolsk syndrom, dyslipidemi, Alzheimers sykdom, sepsis, inflammatoriske sykdommer så som kolitt, pankreatitt, kolestase/fibrose i leveren og sykdommer som har en inflammatorisk komponent så som Alzheimers sykdom eller svekket/forbedrrbar kognitiv funksjon.
NO20064820A 2004-03-26 2006-10-24 Tetrahydrokarbazoler og derivater NO20064820L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101252 2004-03-26
PCT/EP2005/002869 WO2005092856A1 (en) 2004-03-26 2005-03-17 Tetrahydrocarbazoles and derivatives

Publications (1)

Publication Number Publication Date
NO20064820L true NO20064820L (no) 2006-10-24

Family

ID=34963176

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064820A NO20064820L (no) 2004-03-26 2006-10-24 Tetrahydrokarbazoler og derivater

Country Status (27)

Country Link
US (2) US20050215577A1 (no)
EP (1) EP1732892B1 (no)
JP (1) JP4705630B2 (no)
KR (1) KR100803478B1 (no)
CN (1) CN1938273B (no)
AR (1) AR048334A1 (no)
AT (1) ATE408599T1 (no)
AU (1) AU2005225524B2 (no)
BR (1) BRPI0509275A (no)
CA (1) CA2560700A1 (no)
DE (1) DE602005009811D1 (no)
DK (1) DK1732892T3 (no)
ES (1) ES2314633T3 (no)
HK (1) HK1101911A1 (no)
HR (1) HRP20080651T3 (no)
IL (1) IL177704A (no)
MX (1) MXPA06010815A (no)
MY (1) MY140874A (no)
NO (1) NO20064820L (no)
NZ (1) NZ549396A (no)
PL (1) PL1732892T3 (no)
PT (1) PT1732892E (no)
RU (1) RU2382770C2 (no)
SI (1) SI1732892T1 (no)
TW (1) TW200539870A (no)
WO (1) WO2005092856A1 (no)
ZA (1) ZA200607491B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101595096B (zh) 2006-11-30 2012-06-27 兴和株式会社 取代甲醇化合物
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
US7919509B2 (en) * 2008-02-29 2011-04-05 Kowa Company, Ltd. 2-oxochromene derivatives
US20110060580A1 (en) * 2008-03-17 2011-03-10 Joerg Benz Lxr ligand binding domain (lxr lbd) crystals
JP5511080B2 (ja) * 2008-03-31 2014-06-04 興和株式会社 １，３−ジヒドロイソベンゾフラン誘導体
EP2272843A4 (en) * 2008-04-30 2011-07-20 Kowa Co QUINOLINE COMPOUND
US8153634B2 (en) * 2008-05-29 2012-04-10 Kowa Company, Ltd. Carbinol derivatives having cyclic linker
FR2938537B1 (fr) 2008-11-14 2012-10-26 Sanofi Aventis Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.
NZ595910A (en) * 2009-04-29 2013-06-28 Kowa Co Carbinol compound having heterocyclic linker
WO2012043791A1 (ja) 2010-10-01 2012-04-05 大正製薬株式会社 １，２，４-トリアゾロン誘導体
DE102011055815A1 (de) 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
CN107674071B (zh) * 2012-05-11 2021-12-31 同步制药公司 作为隐花色素调节剂的含有咔唑的磺酰胺类
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
US10000459B2 (en) 2013-03-15 2018-06-19 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
CN103910659B (zh) * 2013-11-04 2016-05-11 迈克斯(如东)化工有限公司 2-硝基-4-甲磺酰基苯甲酸的精制方法及其中间体
RU2648236C2 (ru) 2013-12-13 2018-03-23 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
WO2017023916A1 (en) 2015-08-05 2017-02-09 Georgetown University Small molecule androgen receptor inhibitors and methods of use thereof
EP3402477A4 (en) 2016-01-11 2019-08-21 The Rockefeller University METHODS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH SUPPRESSIVE CELLS DERIVED FROM MYELOID CELLS
WO2019104062A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
US20200085810A1 (en) 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
US11174220B2 (en) 2019-12-13 2021-11-16 Inspirna, Inc. Metal salts and uses thereof
CN111518002B (zh) * 2020-05-21 2022-06-21 南京林业大学 一种硫醚类化合物及其制备方法、医药中间体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090732A1 (en) * 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha Lxr modulators for the treatment of cardiovascular diseases
WO2003090746A1 (en) * 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
CA2486651A1 (en) * 2002-05-24 2003-12-04 Pharmacia Corporation Sulfone liver x-receptor modulators
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
AU2003256655A1 (en) * 2002-07-25 2004-02-16 Merck And Co., Inc. Therapeutic compounds for treating dyslipidemic conditions

Also Published As

Publication number Publication date
JP4705630B2 (ja) 2011-06-22
US20050215577A1 (en) 2005-09-29
RU2382770C2 (ru) 2010-02-27
AR048334A1 (es) 2006-04-19
WO2005092856A1 (en) 2005-10-06
IL177704A0 (en) 2006-12-31
ZA200607491B (en) 2008-06-25
EP1732892A1 (en) 2006-12-20
IL177704A (en) 2011-09-27
NZ549396A (en) 2010-04-30
CN1938273B (zh) 2011-12-14
SI1732892T1 (sl) 2009-02-28
RU2006137655A (ru) 2008-05-10
AU2005225524A1 (en) 2005-10-06
TW200539870A (en) 2005-12-16
CN1938273A (zh) 2007-03-28
PL1732892T3 (pl) 2009-03-31
HRP20080651T3 (en) 2009-01-31
US20100216833A1 (en) 2010-08-26
ATE408599T1 (de) 2008-10-15
BRPI0509275A (pt) 2007-09-04
AU2005225524B2 (en) 2007-11-22
KR20060124780A (ko) 2006-12-05
US7906546B2 (en) 2011-03-15
DK1732892T3 (da) 2009-01-05
JP2007530480A (ja) 2007-11-01
HK1101911A1 (en) 2007-11-02
CA2560700A1 (en) 2005-10-06
ES2314633T3 (es) 2009-03-16
KR100803478B1 (ko) 2008-02-14
DE602005009811D1 (de) 2008-10-30
MY140874A (en) 2010-01-29
MXPA06010815A (es) 2006-12-15
PT1732892E (pt) 2008-12-22
EP1732892B1 (en) 2008-09-17
WO2005092856A8 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
NO20064820L (no) Tetrahydrokarbazoler og derivater
AU2022201816A8 (en) Pyrrolopyrimidines as CFTR potentiators
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
WO2008005569A3 (en) Modulators of metabolism and the treatment of disorders related thereto
EA200801417A1 (ru) Соединение бициклического циннамида
EA200970090A1 (ru) Модуляторы метаболизма и лечение связанных с ним расстройств
NO20064456L (no) Thiadiazolidinoner som GSK-3 inhibitorer
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
NO20083642L (no) Dibenzylaminderivater som CETP-inhibitorer
EA200701746A1 (ru) Фармацевтические композиции для лечения или профилактики заболеваний, в том числе ожирения, диабета, метаболического синдрома, нейродегенеративных заболеваний и заболеваний, связанных с нарушением деятельности митохондрий
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
WO2008005534A3 (en) Orally dissolving formulations of memantine
WO2008033460A3 (en) Treating pain, diabetes, and lipid metabolism disorders
ATE429430T1 (de) Stoffwechselmodulatoren und behandlung damit verbundener erkrankungen
WO2003066629A3 (en) Heteroaryl compounds useful as inhibitors of gsk-3
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
NO20055680L (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
NO20074872L (no) Pyrazoler
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
NO20080554L (no) Pyrazolonderivater
NO20072389L (no) Substituerte benzokinolizinderivater
NO20083562L (no) Cannabinoidreseptormodulatorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application